Gelonghui, November 29丨Shanghai Pharmaceutical (601607.SH) announced that the company signed a “Cooperation Agreement” with Shuntian Pharmaceutical Biotechnology Co., Ltd. to obtain exclusive rights in the development, production and sale of I037 (hereinafter referred to as “LT3001” or “this project”) in mainland China (see Company Notice No. 2019-085 for details). In September 2020, the project was approved by the State Drug Administration to carry out clinical trials (see Company Notice No. 2020-52 for details). Recently, the company completed the analysis of LT3001 phase II clinical trial results in China.
LT3001 for injection is the world's first innovative drug project for acute stroke treatment combining targeted thrombolysis and neuroprotective functions. It is intended to be used in the treatment of acute ischemic stroke.
